Sept 27 (Reuters) - Nykode Therapeutics Asa NYKD.OL :
* NYKODE THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM THE
PHASE
1/2 OPEN LABEL, DOSE ESCALATION TRIAL OF ITS T CELL FOCUSED
SARS-COV-2 VACCINE CANDIDATE
* NYKODE'S VACCINE CANDIDATE WAS SAFE AND WELL-TOLERATED AT
ALL
THREE DOSE LEVELS
* NYKODE-CANDIDATE IS EXPECTED TO RETAIN EFFICACY
INDEPENDENT OF
FUTURE SPIKE MUTATIONS,WOULD NOT NEED TO BE UPDATED FOR FUTURE
VARIANTS OF CONCERN
Source text for Eikon: ID:nGNX6XmhVH
Further company coverage: NYKD.OL
((Reuters.Briefs@thomsonreuters.com;))